Apomorphine is a well established treatment for the management of sudden, unexpected and refractory levodopa-induced “off” states in fluctuating Parkinson’s disease either as bolus injections or as continuous infusions. Incidents of atrial fibrillation associated with the administration of the drug have been reported in the past but no incidents of ventricular arrhythmias. We report a case of ventricular bigeminy recorded in a female patient after the administration of apomorphine.

Citations

Citations to this article as recorded by  

• Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance
  Luca Marsili, Matteo Bologna, Janis M. Miyasaki, Carlo Colosimo
  Parkinsonism & Related Disorders.2021; 83: 132.     CrossRef
• Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease
  Mohammad Al Majali, Michael Sunnaa, Pratap Chand
  Journal of Geriatric Psychiatry and Neurology.2021; 34(4): 263.     CrossRef
• Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients
  Martin Klietz, Stephan Greten, Florian Wegner, Günter U. Höglinger
  Drugs & Aging.2019; 36(6): 511.     CrossRef
• Pharmacological Insights into the Use of Apomorphine in Parkinson’s Disease: Clinical Relevance
  Manon Auffret, Sophie Drapier, Marc Vérin
  Clinical Drug Investigation.2018; 38(4): 287.     CrossRef
• Cardiac abnormalities in Parkinson’s disease and Parkinsonism
  Fulvio A. Scorza, Ana C. Fiorini, Carla A. Scorza, Josef Finsterer
  Journal of Clinical Neuroscience.2018; 53: 1.     CrossRef
• Apomorphine en perfusion sous-cutanée continue dans la maladie de Parkinson : le point de vue pharmacologique
  M. Auffret, S. Drapier, M. Vérin, P. Sauleau
  Pratique Neurologique - FMC.2016; 7(1): 25.     CrossRef
• Practical management of adverse events related to apomorphine therapy
  Roongroj Bhidayasiri, Pedro J. Garcia Ruiz, Tove Henriksen
  Parkinsonism & Related Disorders.2016;[Epub]     CrossRef